Patents Assigned to ARIZONA CANCER THERAPEUTICS L.L.C.
  • USE OF THERAPEUTIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCER
    Publication number: 20160082082
    Abstract: MUC1 (DF3, CD227, episialin, PEM) is a heavily O-glycosylated heterodimeric protein of >300 kDa, normally expressed abundantly on the apical surface of glandular epithelia. MUC1 mimetic peptides are selectively retained in mammary gland tumors, colon and skin after systemic administration. Moreover, MUC1 mimetic peptides reduce tumor initiation. In addition, MUC1 mimetic peptides can be used in conjunction with other anti-EGFR treatments in the adjuvant context, i.e., after surgery.
    Type: Application
    Filed: September 9, 2015
    Publication date: March 24, 2016
    Applicant: ARIZONA CANCER THERAPEUTICS L.L.C.
    Inventor: JOYCE A. SCHROEDER